Review Article
Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban
Table 1
Pharmacokinetic properties of dabigatran, rivaroxaban, and apixaban.
| | Dabigatran [18] | Rivaroxaban [19] | Apixaban [20] |
| Prodrug | Dabigatran etexilate | No | No | Bioavailability | 6.5%, pH sensitive | 80% | 50% | Time to peak, h | 0.5–2 | 2–4 | 3-4 h | Plasma halflife, h | 12–14 | 9–13 | 8–15 | Renal elimination of active drug | 85% | 33% | 27% | Liver CYP3A4 substrate | No | Yes | Yes | P-glycoprotein substrate | Dabigatran etexilate, but not dabigatran | Yes | Yes | Protein binding | 34-35% | 92–95% | 87% | Dialysability | Yes | Not expected | Unlikely |
|
|